TY - JOUR
T1 - IGHV unmutated status influences outcome more than IGHV1-69 gene usage per se in patients with chronic lymphocytic leukemia
AU - Orlandi, Ester
AU - Zibellini, Silvia
AU - Pascutto, Cristiana
AU - Picone, Cristina
AU - Giardini, Ilaria
AU - Pochintesta, Lara
AU - Lazzarino, Mario
PY - 2009/10/1
Y1 - 2009/10/1
N2 - In this study, IGHV1-69 gene usage was detected in 46 out of 379 cases (12%) of chronic lymphocytic leukemia (CLL). In comparison with patients using alternative immunoglobulin heavy-chain variable (IGHV) genes, patients with IgHV1-69 CLLs more often presented at advanced stage, lacked somatic hypermutation (unmutated cases, 87% vs. 35%; P = .00001), and expressed unfavorable biologic characteristics. In 12 patients (26%), common amino acid motifs within the heavy-chain third complementarity-determining region were identified, allowing assignment to previously reported stereotyped subsets. In our study, treatment-free survival of patients with unmutated IGVH1-69 did not differ significantly from that of patients expressing unmutated alternative IGHV genes. As such, IGHV1-69 gene usage per se did not seem to be predictive of progressive disease, progression being primarily related to the unmutated IGHV profile.
AB - In this study, IGHV1-69 gene usage was detected in 46 out of 379 cases (12%) of chronic lymphocytic leukemia (CLL). In comparison with patients using alternative immunoglobulin heavy-chain variable (IGHV) genes, patients with IgHV1-69 CLLs more often presented at advanced stage, lacked somatic hypermutation (unmutated cases, 87% vs. 35%; P = .00001), and expressed unfavorable biologic characteristics. In 12 patients (26%), common amino acid motifs within the heavy-chain third complementarity-determining region were identified, allowing assignment to previously reported stereotyped subsets. In our study, treatment-free survival of patients with unmutated IGVH1-69 did not differ significantly from that of patients expressing unmutated alternative IGHV genes. As such, IGHV1-69 gene usage per se did not seem to be predictive of progressive disease, progression being primarily related to the unmutated IGHV profile.
KW - Binet stage
KW - CD38
KW - Gene rearrangement
KW - HCDR3
KW - ZAP70
UR - http://www.scopus.com/inward/record.url?scp=70350686475&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=70350686475&partnerID=8YFLogxK
U2 - 10.3816/CLM.2009.n.076
DO - 10.3816/CLM.2009.n.076
M3 - Article
C2 - 19858060
AN - SCOPUS:70350686475
VL - 9
SP - 390
EP - 393
JO - Clinical Lymphoma and Myeloma
JF - Clinical Lymphoma and Myeloma
SN - 1557-9190
IS - 5
ER -